Dexrazoxane inhibits the growth of esophageal squamous cell carcinoma by attenuating SDCBP/MDA-9/syntenin-mediated EGFR-PI3K-Akt pathway activation

Ruijuan Du,Nan Xiao,Li Han,KeLei Guo,Kai Li,Zhiguo Chen,Hui Zhang,Zijun Zhou,Yunlong Huang,Xulin Zhao,Hua Bian

DOI: https://doi.org/10.1038/s41598-024-59665-5

IF: 4.6

2024-04-23

Scientific Reports

Abstract:Syndecan-binding protein (SDCBP) was reported to stimulate the advancement of esophageal squamous cell carcinoma (ESCC) and could potentially be a target for ESCC treatment. There is a growing corpus of research on the anti-tumor effects of iron chelators; however, very few studies have addressed the involvement of dexrazoxane in cancer. In this study, structure-based virtual screening was employed to select drugs targeting SDCBP from the Food and Drug Administration (FDA)-approved drug databases. The sepharose 4B beads pull-down assay revealed that dexrazoxane targeted SDCBP by interacting with its PDZ1 domain. Additionally, dexrazoxane inhibited ESCC cell proliferation and anchorage-independent colony formation via SDCBP. ESCC cell apoptosis and G2 phase arrest were induced as measured by the flow cytometry assay. Subsequent research revealed that dexrazoxane attenuated the binding ability between SDCBP and EGFR in an immunoprecipitation assay. Furthermore, dexrazoxane impaired EGFR membrane localization and inactivated the EGFR/PI3K/Akt pathway. In vivo, xenograft mouse experiments indicated that dexrazoxane suppressed ESCC tumor growth. These data indicate that dexrazoxane might be established as a potential anti-cancer agent in ESCC by targeting SDCBP.

multidisciplinary sciences

What problem does this paper attempt to address?

The paper aims to address key issues in the treatment of esophageal squamous cell carcinoma (ESCC), particularly by exploring a new therapeutic approach. Specifically, the study focuses on the role of syndecan-binding protein (SDCBP) in the development of ESCC and attempts to find drugs that can target SDCBP to inhibit the growth of cancer cells.

The main objectives include:
1. **Validate Dexrazoxane as a potential anti-cancer drug**: Inhibit the proliferation of ESCC cells by targeting SDCBP.
2. **Explore the mechanism of action of Dexrazoxane**: Investigate how Dexrazoxane inhibits the activation of the EGFR/PI3K/Akt signaling pathway by interfering with the interaction between SDCBP and the epidermal growth factor receptor (EGFR).
3. **Evaluate the in vivo anti-tumor effects of Dexrazoxane**: Verify the inhibitory effect of Dexrazoxane on ESCC tumor growth using a mouse xenograft model.

In summary, this study aims to demonstrate the effectiveness of Dexrazoxane as a new anti-cancer drug in inhibiting ESCC cell proliferation, inducing apoptosis, and blocking the G2 phase, as well as to verify its anti-tumor activity in vivo.